Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 959 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Escalation Clear all

Conditions: Glioblastoma, Recurrent Glioblastoma
Interventions: Pembrolizumab, Olaparib, Temozolomide; Drug
Lead sponsor: L. Nicolas Gonzalez Castro, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York

Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions: PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more

Conditions: Selected Types of Solid Tumor
Interventions: EVM14, Pembrolizumab; Biological · Combination Product
Lead sponsor: Everest Medicines (Beijing) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: New York, New York • Houston, Texas • Fairfax, Virginia

Conditions: Barrett Esophagus
Interventions: placebo, defined green tea catechin extract; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: New York, New York • Houston, Texas

Conditions: Myeloid Malignancy
Interventions: PMD-026; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Li-Fraumeni Syndrome
Interventions: Metformin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Graft Versus Host Disease, Hematologic Neoplasms
Interventions: Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: erlotinib hydrochloride, quinacrine dihydrochloride - Escalation dose, laboratory biomarker analysis, pharmacological study, quinacrine dihydrochloride - Extension dose; Drug · Other
Lead sponsor: Neelesh Sharma MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity
Interventions: JNJ-64565111; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Sarcoma, Osteosarcoma
Interventions: Domatinostat, Sirolimus; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 12 Years to 40 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Tampa, Florida • St Louis, Missouri • The Bronx, New York + 1 more

Conditions: Parotid Neoplasm, Thyroid Neoplasms, Head and Neck Neoplasms, Surgery, Nerve Injury, Imaging
Interventions: Bevonescein; Drug
Lead sponsor: Alume Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: San Diego, California • Stanford, California • Boston, Massachusetts

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: Vorinostat, Pembrolizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Indolent B-Cell Non-Hodgkin Lymphoma
Interventions: BI-1206, Rituximab, Acalabrutinib; Biological
Lead sponsor: BioInvent International AB; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia • Louisville, Kentucky

Conditions: Breast Cancer
Interventions: Temsirolimus, Neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 4
States / cities: Goodyear, Arizona • Los Angeles, California • New York, New York

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Interventions: Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine, Venetoclax; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 24
States / cities: Los Angeles, California • Orange, California • New Haven, Connecticut + 18 more

Conditions: Gastric Cancer
Interventions: Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, Cisplatin, Pembrolizumab, Volrustomig, Rilvegostomig; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions: pNGVL4aCRTE6E7L2; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 19 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Conditions: Refractory Partial Seizures
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia
Interventions: Ruxolitinib, Cladribine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematologic Malignancies
Interventions: SLS009, venetoclax, azacitidine; Drug
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more

Conditions: Heart Failure
Interventions: LCZ 696, Placebo, Para-aminohippurate, Iohexol, Aprepitant; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
Interventions: TRK-950; Biological
Lead sponsor: Toray Industries, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Phoenix, Arizona • Scottsdale, Arizona

Conditions: BRAF Mutant Metastatic Melanoma
Interventions: BKM120 Combined with Vemurafenib (PLX4032); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Peanut Allergy
Interventions: ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal, Placebo Intramuscular; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more

Search by objective public record fields.

Surgical Pembro +/- Olaparib w TMZ for rGBM

A Study of PF-06873600 in People With Cancer

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus

Therapeutic RSK1 Targeting in Myeloid Malignancies

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Optimizing PTCy Dose and Timing

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine